Crucell corporate brochure (PDF)

Crucell’s commitment to the world – Taking responsibility
CSR highlights in 2010
y A CSR Working Group was established in the first quarter of 2010
and has driven the implementation of Crucell’s global policy for
evidence-based CSR development and reporting.
y The initial set of ambitions, targets and key performance indicators
in the CSR 4P framework categories of Performance, People, Planet
and Philanthropy have been reviewed, revised and expanded
where necessary.
y A centralized system for CSR information management has been
developed and rolled out worldwide, and company-wide data
collected for baseline assessments.
y For the second successive year, Crucell was listed on the Dow Jones
Sustainability Index (DJSI) in 2010 and showed strong progress on
the Dutch ‘Transparency Benchmark’.
y Crucell CEO Ronald Brus was nominated by the vaccine industry
of industrialized countries to represent the constituency on the
Board of the GAVI Alliance, a public-private partnership dedicated
to improving access to new and underused vaccines in the world’s
poorest countries.
y Hundreds of talented people were recruited and further operational
improvements were made in order to boost Crucell’s capacity to
bring innovation to global health.
y A range of global initiatives were launched to foster employees’
learning and development, which has been identified as the CSR
priority with respect to human resources.
y Crucell made important advances towards responsible supply
chain management.
y Crucell partnered the International Pediatric Association,
the nongovernmental organization (NGO) Friendship and other
organizations in their great efforts to support national vaccination
programs in developing countries, as well as other NGOs such as
the Max Foundation.
y ‘Footprint’, Crucell’s community outreach program, expanded in
scope and impact. Two field trips made an indelible impression on
the lives of participating employees from different Crucell offices
around the world, as well as the people living in disadvantaged
communities in South Africa and Bangladesh.
y The success of Crucell’s collaboration with Johnson & Johnson on
research and development (R&D) projects during 2010 prompted both
parties to explore the possibility of closer ties. This led to Crucell
joining the Johnson & Johnson Family of Companies in February 2011,
in what we see as an exciting advance for world health.
“ Our CSR program is a concerted effort
to ensure that we maximize the benefits
we bring to society while minimizing
our environmental footprint.”
35